But there's a powerful fundamental story happening with Eli Lilly. Also, EPS is estimated to ramp higher this year by +21.7%.

Eli Lilly is upgraded to Buy after a 13% pullback and strong Q4 guidance, with potential for 25% topline growth in 2026. LLY's acquisition of Kelonia and Orna Therapeutics positions it at the ...

Eli Lilly topped Novo in terms of both revenue and net income. Moderna’s stable financials were overshadowed by the regulatory whiplash it experienced in mid-February. Similarly, the vaccine segments ...

Mon, February 16, 2026 at 7:00 PM UTC As of February 13, 2026, shares of Eli Lilly (NYSE:LLY) were trading at $1,040, just 5.8% below the stock's all-time high. Retail sentiment has turned decisively ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at branded pharmaceuticals stocks, starting ...

Lilly closed 2025 with back-to-back blowout quarters. Q4 revenue hit $19.29 billion against a consensus estimate of $18.14 billion, while non-GAAP EPS of $7.54 cleared the $6.74 estimate by nearly 12% ...

Eli Lilly is included due to its strategic positioning with respect to sustainability opportunities, specifically in HealthCare Access and Innovation. Advanced Micro Devices is owned for its ...

RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark Large Growth Fund” Q4 2025 investor letter. A copy of the letter can be ...

Jensen Investment Management, an asset management company based in the US, released its fourth-quarter investor letter for “Jensen Quality Growth Equity Strategy”. A copy of the letter can be ...